Table 3.

Clinical Outcomes at 12 Months in Patients Assigned to 3‐Month Dual Antiplatelet Therapy, Grouped by Stent Types

	Stent Types		Unadjusted		Propensity‐Score Matching		Inverse‐Probability Weighted
	Orsiro (n=481)	EES (n=1014)	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Target vessel failure	8 (1.7)	17 (1.8)	0.96 (0.41–2.22)	0.92	0.80 (0.31–2.04)	0.64	0.92 (0.40–2.15)	0.85
Cardiac death	2 (0.4)	9 (0.9)	0.46 (0.10–2.13)	0.32	0.40 (0.08–2.06)	0.27	0.36 (0.08–1.66)	0.19
Target vessel–related myocardial infarction	1 (0.2)	3 (0.3)	0.69 (0.07–6.66)	0.75	0.33 (0.03–3.20)	0.34	0.67 (0.07–6.39)	0.73
Target vessel revascularization	6 (1.4)	6 (0.6)	2.08 (0.67–6.43)	0.21	2.01 (0.50–8.09)	0.33	2.10 (0.67–6.58)	0.20
All‐cause death	5 (1.1)	16 (1.6)	0.65 (0.24–1.78)	0.40	0.62 (0.20–1.91)	0.41	0.52 (0.19–1.40)	0.19
Any myocardial infarction	2 (0.4)	9 (0.9)	0.46 (0.10–2.13)	0.32	0.25 (0.05–1.17)	0.08	0.54 (0.12–2.54)	0.44
Repeated revascularization	11 (2.4)	13 (1.4)	1.76 (0.79–3.93)	0.17	1.58 (0.61–4.12)	0.35	1.71 (0.77–3.82)	0.19
Stent thrombosis	0	3 (0.3)	…	…	…	…	…	…

Data are n or n (%). The percentages are Kaplan–Meier estimates. EES indicates everolimus‐eluting stent; and HR, hazard ratio.